SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : North American Vaccine
NVX 1.370-1.4%Jan 15 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Don W Stone who wrote (311)2/25/1998 6:54:00 PM
From: David Bogdanoff  Read Replies (2) of 507
 
DWS:

Thanks for your thoughts and input. Although it is exciting to see other companies go after the vaccine market, thus validating NVX's business franchise, doesn't this mean competition, even if it is high cost competition? And doesn't the extensive in-house vaccine development of these big pharma companies obviate the need to buy out NVX? Regarding, conjugate vaccine technology, I did not understand from the article that the bioengineering approach relied upon such technology. If it did I assume that we would have heard about a licensing agreement with NVX. I am aware of a licensing agreement between a big pharma company with Vical for naked gene technology for a vaccine against HIV, but that does not seem to be conjugate vaccine technology. NVX is not biotech company. After thinking about it, it seems to me that the article deals with a competing technology which probably represent competition for big markets. Guess that's both good and bad news.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News